SOHM, Inc. SHMN
0.00 USD 0.00 (+10.45%)
At closeNov 2, 2026, 4:00 PM EST
0.0008 Day range 0.0008
0.0006 52-week range 0.0015
- YTD
- -17.78%
- 1 year
- -32.73%
- Market cap
- 2.14M
- EPS (ttm)
- -0.002
- YTD return
- -17.78%
- 1-year return
- -32.73%
- Volume
- 2.49M
- Avg volume
- 918.24K
- Open
- 0.0008
- Previous close
- 0.00067
- Day's range
- 0.0008 – 0.0008
- 52-week range
- 0.0006 – 0.0015
2Y -0.0003 (-27.27%)
Financials — quick view
SHMN Revenue — quarterly 231.86K
SHMN Net income — quarterly -249.58K
SHMN EPS — quarterly 0.00
News
SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery 
SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development 
SOHM, Inc., Moving and Expanding Commercialization Capabilities with its New Vista, CA Facility 
SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities 
SOHM, Inc. Launches New User-Friendly Website to Enhance Customer, Investor Experience and Engagement 
SOHM, Inc. Appoints Ravi Kapoor as an Independent Director 
SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market 
SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations 
SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development 
SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
Your note
Sign in to keep a note on SHMN — it syncs with the Stock Master app.